Yukinori Minoshima
Overview
Explore the profile of Yukinori Minoshima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eng J, Kato Y, Adachi Y, Swaminathan B, Naiche L, Vadakath R, et al.
Cancer Res Commun
. 2024 Jul;
4(7):1881-1893.
PMID: 38984877
Significance: A first-in-class anti-Notch4 agent, E7011, demonstrates strong antitumor effects in murine tumor models including breast carcinoma. Endothelial Notch4 blockade reduces perfusion and vessel area.
2.
Makker V, Taylor M, Aghajanian C, Cohn A, Brose M, Di Simone C, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38242717
Background: Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated the...
3.
Niwa Y, Adachi K, Tabata K, Ishida R, Hotta K, Ishida T, et al.
Mol Cancer Ther
. 2023 Jan;
22(4):499-510.
PMID: 36696578
Eribulin is a microtubule dynamics inhibitor with tumor microenvironment modulation activity such as vascular remodeling activity. Here, we investigated antitumor and immunomodulatory activities of eribulin and its liposomal formulation (eribulin-LF)...
4.
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
Kitano S, Fujiwara Y, Shimizu T, Iwasa S, Yonemori K, Kondo S, et al.
Cancer Chemother Pharmacol
. 2022 Oct;
90(6):523-529.
PMID: 36289094
Purpose: Combination treatment using lenvatinib (a multikinase inhibitor) plus pembrolizumab (a programmed death-1 immune checkpoint inhibitor) has shown efficacy in the treatment of endometrial and renal cell cancers. This phase...
5.
Finn R, Kudo M, Cheng A, Wyrwicz L, Ngan R, Blanc J, et al.
Clin Cancer Res
. 2021 Jun;
27(17):4848-4858.
PMID: 34108184
Purpose: In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This analysis assessed correlations between serum or tissue biomarkers...
6.
Lee C, DiNatale R, Chowell D, Krishna C, Makarov V, Valero C, et al.
Mol Cancer Res
. 2021 May;
19(9):1510-1521.
PMID: 34039647
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have...
7.
Lee C, Motzer R, Glen H, Michaelson M, Larkin J, Minoshima Y, et al.
Br J Cancer
. 2020 Oct;
124(1):237-246.
PMID: 33024271
Background: No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores...
8.
Ichikawa K, Miyano S, Minoshima Y, Matsui J, Funahashi Y
Sci Rep
. 2020 Feb;
10(1):2939.
PMID: 32076044
Anti-vascular endothelial growth factor (VEGF) therapy shows antitumor activity against various types of solid cancers. Several resistance mechanisms against anti-VEGF therapy have been elucidated; however, little is known about the...
9.
Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al.
Cancer Med
. 2018 May;
7(6):2641-2653.
PMID: 29733511
Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent cancers worldwide, and current systemic therapeutic options for uHCC are limited. Lenvatinib, a multiple receptor tyrosine kinase inhibitor...
10.
Uehara T, Minoshima Y, Sagane K, Sugi N, Mitsuhashi K, Yamamoto N, et al.
Nat Chem Biol
. 2017 Apr;
13(6):675-680.
PMID: 28437394
Target-protein degradation is an emerging field in drug discovery and development. In particular, the substrate-receptor proteins of the cullin-ubiquitin ligase system play a key role in selective protein degradation, which...